C of A [GxP / QC / QA]

posted by Ohlbe – France, 2011-02-21 20:09 (5191 d 14:31 ago) – Posting: # 6655
Views: 7,372

Dear Dan,

If the drug was sampled from the local market, there is indeed no real problem. I'm more concerned about a product sampled from a foreign market. Think how the BfArM would react if you intended to run a study in Germany with a non-EU product, without a release by a QP. But it may actually be a regulatory issue as much as an ethical question.

Regards
Ohlbe

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
124 visitors (0 registered, 124 guests [including 14 identified bots]).
Forum time: 11:41 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5